Bone Growth Factor Market Offers Attractive Niche For Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Medtronic/Sofamor Danek expects to submit clinical data supporting a premarket approval application for its InFuse BMP-2 recombinant bone morphogenic protein by mid-year. The company is hoping for expedited FDA review of the product, with a possible rollout by 2002.
You may also be interested in...
Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA
Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.
Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA
Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.
OrthoLogic Rehab Divestiture Will Fund Chrysalin Osteobiologics Development
OrthoLogic is planning to divest its $60 mil. orthopedic rehabilitation device business and use the proceeds for further development of the osteobiologic product Chrysalin, and to expand the company's remaining fracture healing and spinal repair business, including possible acquisitions.